Mutations in DOCK8 result in autosomal recessive Hyper-IgE syndrome with combined immunodeficiency (CID). However, the natural course of disease, long-term prognosis, and optimal therapeutic management have not yet been clearly defined. In an international retrospective survey of patients with DOCK8 mutations, focused on clinical presentation and therapeutic measures, a total of 136 patients with a median follow-up of 11.3 years (1.3-47.7) spanning 1693 patient years, were enrolled. Eczema, recurrent respiratory tract infections, allergies, abscesses, viral infections and mucocutaneous candidiasis were the most frequent clinical manifestations. Overall survival probability in this cohort [censored for hematopoietic stem cell transplantation (HSCT)] was 87 % at 10, 47 % at 20, and 33 % at 30 years of age, respectively. Event free survival was 44, 18 and 4 % at the same time points if events were defined as death, life-threatening infections, malignancy or cerebral complications such as CNS vasculitis or stroke. Malignancy was diagnosed in 23/136 (17 %) patients (11 hematological and 9 epithelial cancers, 5 other malignancies) at a median age of 12 years. Eight of these patients died from cancer. Severe, life-threatening infections were observed in 79/136 (58 %); severe non-infectious cerebral events occurred in 14/136 (10 %). Therapeutic measures included antiviral and antibacterial prophylaxis, immunoglobulin replacement and HSCT. This study provides a comprehensive evaluation of the clinical phenotype of DOCK8 deficiency in the largest cohort reported so far and demonstrates the severity of the disease with relatively poor prognosis. Early HSCT should be strongly considered as a potential curative measure.
Autosomal recessive osteopetrosis is usually associated with normal or elevated numbers of nonfunctional osteoclasts. Here we report mutations in the gene encoding RANKL (receptor activator of nuclear factor-KB ligand) in six individuals with autosomal recessive osteopetrosis whose bone biopsy specimens lacked osteoclasts. These individuals did not show any obvious defects in immunological parameters and could not be cured by hematopoietic stem cell transplantation; however, exogenous RANKL induced formation of functional osteoclasts from their monocytes, suggesting that they could, theoretically, benefit from exogenous RANKL administration.
BackgroundImmunodysregulation polyendocrinopathy enteropathy x-linked(IPEX) syndromeis a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined.ObjectiveThis analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors.MethodsClinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed.ResultsWe confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS.ConclusionsPatients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.
Background
Intravenous-busulfan (IV-busulfan) combined with therapeutic drug
monitoring to guide dosing improves outcomes after allogeneic hematopoietic
cell transplantation (allo-HCT). The best method to estimate busulfan
exposure and the optimal exposure in children/young adults remains unclear.
We therefore evaluated three approaches to estimate IV-Bu exposure
(expressed as cumulative-area-under-the-curve; AUC) and associated
busulfan-AUC with clinical outcomes in children/young adults undergoing
allo-HCT.
Methods
In this retrospective analysis, patients (0.1–30.4 years)
receiving busulfan-based conditioning regimen from 15 centers were included.
Cumulative AUC was calculated by numerical integration using non-linear
mixed effect modeling (AUCNONMEM), non-compartmental analysis
(AUC0-infinity and AUC to the end of the dose interval
AUC0-tau) and by individual centers using a variety of
approaches (AUCcenter). Main outcome of interest was event-free
survival (EFS). Other outcomes of interest were overall survival,
graft-failure, relapse, transplantation related mortality (TRM), acute
toxicity (veno-occlusive disease (VOD) and/or acute graft versus-host
disease (aGvHD), chronic GvHD (cGvHD) and cGVHD-free event-free survival
(GEFS). Propensity score adjusted cox proportional hazard models, Weibull
models, and Fine-Gray competing risk regressions were used.
Results
674 patients were included (41% malignant, 59%
non-malignant) Estimated 2-year EFS was 69.7%. The median busulfan
AUCNONMEM was 74.4 mg*h/L (CI95% 31.1–104.6
mg*h/L). The median AUCNONMEM correlated poorly with
AUCcenter (R2 = 0.254). Patients with optimal
IV-busulfan AUC of 78–101 mg*h/L showed 81% EFS at 2 years
compared to 66.1% and 49.5% in the low (<78 mg*h/L)
and high (>101 mg*h/L) busulfan AUC group respectively (P=0.011).
Graft-failure/relapse occurred more frequently in the low AUC group (HR=1.75
P<0.001). Acute toxicity, cGvHD and TRM was significantly higher in
the high AUC group (HR 1.69, 2.99 and 1.30), independent of indication.
Interpretation
These results demonstrate that improved clinical outcomes may be
achieved by targeting the busulfan-AUC to 78–101 mg*h/L using a new
validated pharmacokinetic-model for all indications.
Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency with microthrombocytopenia, eczema, recurrent infections, autoimmune disorders, and malignancies that are life-threatening in the majority of patients. In this long-term, retrospective, multicenter study, we analyzed events that occurred in 96 WAS patients who received transplants between 1979 and 2001 who survived at least 2 years following hematopoietic stem-cell transplantation (HSCT). Events included chronic graft-versus-host disease (cGVHD), autoimmunity, infections, and sequelae of before or after HSCT complications. Three patients (3%) died 2.1 to 21 years following HSCT. Overall 7-year event-free survival rate was 75%. It was lower in recipients of mismatched related donors, also in relation with an older age at HSCT and disease severity. The most striking finding was the observation of cGVHD-independent autoimmunity in 20% of patients strongly associated with a mixed/split chimerism status (P < .001), suggesting that residual-host lymphocytes can mediate autoimmune disease despite the coexistence of donor lymphocytes. Infectious complications (6%) related to splenectomy were also significant and may warrant a more restrictive approach to performing splenectomy in WAS patients. Overall, this study provides the basis for a prospective, standardized, and more in-depth detailed analysis of chimerism and events in longterm follow-up of WAS patients who receive transplants to design better-adapted therapeutic strategies. (Blood. 2008;111: 439-445)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.